Moors & Cabot Inc. Has $402,000 Stake in Sanofi (NASDAQ:SNY)

Moors & Cabot Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 14.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,288 shares of the company’s stock after buying an additional 1,026 shares during the quarter. Moors & Cabot Inc.’s holdings in Sanofi were worth $402,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Cascade Investment Advisors Inc. increased its stake in Sanofi by 4.7% in the first quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock valued at $1,670,000 after purchasing an additional 1,535 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Sanofi in the 4th quarter valued at $14,919,000. Dynamic Advisor Solutions LLC raised its stake in Sanofi by 39.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after buying an additional 16,117 shares during the period. Manning & Napier Advisors LLC bought a new position in Sanofi during the second quarter worth about $13,725,000. Finally, Mount Yale Investment Advisors LLC grew its stake in Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares during the period. 10.04% of the stock is owned by institutional investors.

Sanofi Stock Up 1.4 %

NASDAQ:SNY opened at $58.26 on Friday. The stock has a 50-day simple moving average of $54.08 and a 200 day simple moving average of $50.35. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97. The company has a market cap of $147.56 billion, a PE ratio of 29.28, a PEG ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter in the prior year, the firm posted $0.95 EPS. The business’s revenue was up 7.8% on a year-over-year basis. On average, sell-side analysts expect that Sanofi will post 4.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.